108 related articles for article (PubMed ID: 3459351)
1. A comparison of different formulations and dosage administrations of gemfibrozil.
Kovanen PT; Koskinen P; Manninen V
Am J Cardiol; 1986 May; 57(14):31G-34G. PubMed ID: 3459351
[TBL] [Abstract][Full Text] [Related]
2. Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers.
Koskinen P; Kovanen PT; Tuomilehto J; Manninen V
Arch Intern Med; 1992 Jan; 152(1):90-6. PubMed ID: 1728934
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
[TBL] [Abstract][Full Text] [Related]
4. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
[TBL] [Abstract][Full Text] [Related]
5. Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia.
Lewis JE
Angiology; 1982 Sep; 33(9):603-12. PubMed ID: 6957156
[TBL] [Abstract][Full Text] [Related]
6. Combination drug therapy for familial combined hyperlipidemia.
East C; Bilheimer DW; Grundy SM
Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
[TBL] [Abstract][Full Text] [Related]
7. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
8. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
[TBL] [Abstract][Full Text] [Related]
9. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of gemfibrozil on lipoprotein metabolism.
Saku K; Gartside PS; Hynd BA; Kashyap ML
J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
[TBL] [Abstract][Full Text] [Related]
11. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.
Jones PH; Pownall HJ; Patsch W; Herd JA; Farmer JA; Payton-Ross C; Kimball KT; Gotto AM; Morrisett JD
J Lipid Res; 1996 Jun; 37(6):1298-308. PubMed ID: 8808764
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.
Krause BR; Newton RS
J Lipid Res; 1985 Aug; 26(8):940-9. PubMed ID: 3862732
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
14. Influence of gemfibrozil on high-density lipoproteins.
Glueck C
Am J Cardiol; 1983 Aug; 52(4):31B-34B. PubMed ID: 6577782
[TBL] [Abstract][Full Text] [Related]
15. Effect of gemfibrozil on serum lipids in man.
Fenderson RW; Deutsch S; Menachemi E; Chin B; Samuel P
Angiology; 1982 Sep; 33(9):581-93. PubMed ID: 6751166
[TBL] [Abstract][Full Text] [Related]
16. The Helsinki Heart Study: basic design and randomization procedure.
Mänttäri M; Elo O; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
Eur Heart J; 1987 Oct; 8 Suppl I():1-29. PubMed ID: 3322826
[TBL] [Abstract][Full Text] [Related]
17. Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia.
Torstila I; Kaukola S; Manninen V; Virtamo J; Mälkönen M
Acta Med Scand Suppl; 1982; 668():123-9. PubMed ID: 6188330
[TBL] [Abstract][Full Text] [Related]
18. Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
Houlston R; Quiney J; Watts GF; Lewis B
J R Soc Med; 1988 May; 81(5):274-6. PubMed ID: 3164409
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment.
Stange EF; Osenbrügge M; Rustan M; Reimann F; Schneider A; Ditschuneit HH; Ditschuneit H
Atherosclerosis; 1991 Dec; 91(3):257-65. PubMed ID: 1789808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
